Obstetrics and Gynecology Department, Kasr Alainy Hospital Cairo University, Cairo, Egypt.
Clinical Pathology Department, Kasr Alainy Hospital Cairo University, Cairo, Egypt.
Int J Gynaecol Obstet. 2021 Mar;152(3):395-400. doi: 10.1002/ijgo.13405. Epub 2020 Oct 22.
To investigate whether dual triggering of final oocyte maturation with a combination of gonadotropin-releasing hormone (GnRH) agonist and human chorionic gonadotropin (hCG) can improve the number of retrieved oocytes and clinical pregnancy rate in poor responders undergoing in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI) cycles using a GnRH-antagonist protocol.
A randomized controlled trial included poor ovarian responders indicated for ICSI using a GnRH-antagonist protocol. They were divided equally into two groups: group I received 10 000 units of hCG plus 0.2 mg of triptorelin while group II received 10 000 units of hCG only for triggering of ovulation. The primary outcome parameter was the number of oocytes retrieved. Secondary outcomes included metaphase II oocytes number, cancellation rate, number of obtained embryos, chemical and clinical pregnancy rates.
One hundred and sixty women were included in the study, with 80 women in each treatment group. Dual triggering was associated with higher number of retrieved oocytes (5.3 ± 1.9 vs 4.5 ± 2.4, P=0.014), metaphase II oocytes (3.8 ± 1.4 vs 3.1 ± 1.7, P=0.004), total and grade 1 embryos (2.7 ± 1.1 and 2.3 ± 1.0 vs 1.9 ± 1.2 and 1.1 ± 0.2, P=0.001 and 0.021 respectively), and transferred embryos (2.2 ± 0.9 vs 1.6 ± 0.9, P=0.043, and lower cancellation rate (7.5% vs 20%, P=0.037) compared with single triggering. There were significantly higher chemical (25% vs 11.3%, P=0.039) and clinical (22.5% vs 8.8%, P=0.028) pregnancy rates in women with dual triggering compared with those with single triggering.
Dual triggering is associated with better IVF outcome in poor responders compared with single trigger. Clinical trial registration NCT04008966.
研究在 GnRH 拮抗剂方案的 IVF-ICSI 周期中,使用 GnRH 激动剂和人绒毛膜促性腺激素(hCG)联合双重触发卵母细胞最终成熟是否可以增加获卵数和临床妊娠率。
本随机对照试验纳入了接受 GnRH 拮抗剂方案行 ICSI 的卵巢低反应患者,将其平均分为两组:I 组给予 10000 单位 hCG 加 0.2mg 曲普瑞林,而 II 组仅给予 10000 单位 hCG 触发排卵。主要结局参数是获卵数。次要结局包括 MII 卵数、取消率、获得胚胎数、生化妊娠率和临床妊娠率。
共有 160 名女性入组研究,每组 80 名。双重触发与更高的获卵数(5.3±1.9 比 4.5±2.4,P=0.014)、MII 卵数(3.8±1.4 比 3.1±1.7,P=0.004)、总胚胎数和优质胚胎数(2.7±1.1 和 2.3±1.0 比 1.9±1.2 和 1.1±0.2,P=0.001 和 0.021)和移植胚胎数(2.2±0.9 比 1.6±0.9,P=0.043)相关,且取消率更低(7.5%比 20%,P=0.037)。与单次触发相比,双重触发的化学妊娠率(25%比 11.3%,P=0.039)和临床妊娠率(22.5%比 8.8%,P=0.028)更高。
与单次触发相比,双重触发可改善卵巢低反应患者的 IVF 结局。临床试验注册号 NCT04008966。